A recently published scientific paper by researchers associated with Alertix researchers Liya Wang, Sara Sällström, and Hanan Sharif displays TK1 in cat serum to be significantly higher compared to healthy cats and compared to cats with inflammatory diseases. These results suggest that serum TK1 may be a promising biomarker for the diagnosis and monitoring of
Technical advances offer new potential to TK1 as a tumor biomarker
A recently published review paper highlights TK1 as a tumor biomarker Among other advantages the authors summarize that Authors are Alertix Kiran Kumar Jagarlamudi and Martin Shaw. Read more here
Swedish research behind unique cancer test for pets
Cancer is just as common in companion animals as in humans. Cancer therapy is improving and in many cases the disease can be treated with success. However early diagnosis is crucial for successful treatment. Therefore, a new, unique cancer test can come to be of great significance. The test, which is being developed by the
Animal owners in favor of cancer test
One out of four responding animal owners are in favor of using a test for early detection of cancer in their pets. More than 40 percent are willing to pay equivalent to 70 USD or more of their own money for the test, and 50 percent might consider asking their veterinarian for a test. Alertix
Support from Vinnova
More support for Alertix’ acclaimed research of Alertix screening. This time from Sweden’s Innovation Agency Vinnova. Alertix plans to broaden and deepen its clinical documentation to verify initial results from smaller studies, and receives support from Sweden’s Innovation Agency Vinnova (programme Innovative Startups) to conduct clinical verification studies of its veterinary diagnostic biomarker for tumor
